Mechanism of cytochrome P450‐3A inhibition by ketoconazole

Objectives  Ketoconazole is extensively used as an index inhibitor of cytochrome P450‐3A (CYP3A) activity in vitro and in vivo, but the mechanism of ketoconazole inhibition of CYP3A still is not clearly established.

[1]  D. Greenblatt,et al.  Clinical Studies of Drug–Drug Interactions: Design and Interpretation , 2010 .

[2]  D. Greenblatt,et al.  In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[3]  S D Hall,et al.  Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. , 1994, Biochemical pharmacology.

[4]  G. Miller,et al.  Elucidation of distinct ligand binding sites for cytochrome P450 3A4. , 2000, Biochemistry.

[5]  Hayley S. Brown,et al.  Use of Isolated Hepatocyte Preparations for Cytochrome P450 Inhibition Studies: Comparison with Microsomes for Ki Determination , 2007, Drug Metabolism and Disposition.

[6]  Karthik Venkatakrishnan,et al.  Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions , 2007, Drug Metabolism and Disposition.

[7]  A. D. Rodrigues,et al.  Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[8]  D. Greenblatt,et al.  Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[9]  A. Galetin,et al.  Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[10]  D. Greenblatt,et al.  ATAZANAVIR: EFFECTS ON P-GLYCOPROTEIN TRANSPORT AND CYP3A METABOLISM IN VITRO , 2005, Drug Metabolism and Disposition.

[11]  J B Houston,et al.  CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. , 1999, British journal of clinical pharmacology.

[12]  H. Yamazaki,et al.  Heterotropic cooperativity in oxidation mediated by cytochrome p450. , 2008, Current drug metabolism.

[13]  R. Obach,et al.  Inactivation of Human Cytochrome P450 Enzymes and Drug–Drug Interactions , 2010 .

[14]  D. Greenblatt,et al.  In Vitro Approaches to Anticipating Clinical Drug Interactions , 2007 .

[15]  Aleksandra Galetin,et al.  Modelling atypical CYP3A4 kinetics: principles and pragmatism. , 2005, Archives of biochemistry and biophysics.

[16]  D. Greenblatt,et al.  Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro , 2010, Xenobiotica; the fate of foreign compounds in biological systems.

[17]  L. Wienkers,et al.  Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[18]  J. Houston,et al.  The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions , 2006, Journal of Pharmacology and Experimental Therapeutics.

[19]  P. Dansette,et al.  Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. , 2005, Current drug metabolism.

[20]  D. Greenblatt,et al.  Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. , 2000, The Journal of pharmacology and experimental therapeutics.

[21]  H. Gutfreund,et al.  Enzyme kinetics , 1975, Nature.

[22]  F. Guengerich,et al.  Cooperativity in oxidations catalyzed by cytochrome P450 3A4. , 1997, Biochemistry.

[23]  Kiyomi Ito,et al.  CYP3A4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions , 2005, Journal of Pharmacology and Experimental Therapeutics.

[24]  D. Greenblatt,et al.  Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. , 1994, British journal of clinical pharmacology.

[25]  D. Greenblatt,et al.  Midazolam Hydroxylation by Human Liver Microsomes In Vitro: Inhibition by Fluoxetine, Norfluoxetine, and by Azole Antifungal Agents , 1996, Journal of clinical pharmacology.

[26]  Karthik Venkatakrishnan,et al.  Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models , 2001, Journal of clinical pharmacology.

[27]  D. Greenblatt,et al.  Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. , 1993, Pharmacology.

[28]  Amy Roe,et al.  The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[29]  J. Houston,et al.  Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[30]  J. Houston,et al.  In vitro cytochrome P450 inhibition data and the prediction of drug‐drug interactions: Qualitative relationships, quantitative predictions, and the rank‐order approach , 2005, Clinical pharmacology and therapeutics.

[31]  D. Greenblatt,et al.  Effects of the Antifungal Agents on Oxidative Drug Metabolism , 2000, Clinical pharmacokinetics.

[32]  H. Hachad,et al.  Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis. , 2007, Current drug metabolism.

[33]  Y. Nabuchi,et al.  Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. , 2009, Drug metabolism and pharmacokinetics.

[34]  A. D. Rodrigues,et al.  Enzyme- and transporter-based drug-drug Interactions : progress and future challenges , 2010 .

[35]  D. Greenblatt,et al.  Apparent mechanism‐based inhibition of human CYP3A in‐vitro by lopinavir , 2003, The Journal of pharmacy and pharmacology.

[36]  D. Greenblatt,et al.  Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole , 2000, European Journal of Clinical Pharmacology.

[37]  D. Greenblatt,et al.  In Vitro Prediction of the Terfenadine‐Ketoconazole Pharmacokinetic Interaction , 1994, Journal of clinical pharmacology.

[38]  J. Halpert,et al.  Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J S Harmatz,et al.  Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. , 1996, The Journal of pharmacology and experimental therapeutics.

[40]  P. Thomas,et al.  Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[41]  D. Greenblatt,et al.  Chapter 11:The CYP3 Family , 2008 .